Gesundheit Österreich GmbH - Geschäftsbereich ÖBIG
Pharmaceutical Pricing and Reimbursement Information

Since October 2011 the PPRI website is no longer maintained.

Please refer from now on to the website of the WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies:

Research project

Rationale and objective

In the European Union, pricing and reimbursement of pharmaceuticals is primarily a national competence, and, as a result, 27 different pharmaceutical pricing and reimbursement systems are in place in the enlarged European Union.

The EU Member States have expressed an urgent need for information and data on the pharmaceutical systems in the fellow countries as well as a strong interest in learning about experiences with pricing and reimbursement strategies applied in other countries.

Therefore, the PPRI (Pharmaceutical Pricing and Reimbursement Information) project was launched under the framework of the Public Health Programme 2003–2008, Health information and knowledge 2004. The PPRI research project was commissioned by the European Commission, Health and Consumer Protection Directorate-General (DG SANCO, PPRI project results on DG Sanco's Website) and co-funded by the Austrian Federal Ministry of Health, Family and Youth (BMGFJ).

The overall aim of the PPRI project was to improve information and knowledge on the pharmaceutical systems in the Member States of the enlarged EU, by strengthening the networking of the relevant national authorities and institutions in the field of pharmaceuticals in the EU.

Project organisation

The PPRI project started in April 2005 and ended after a time-frame of two and a half years in October 2007.

The project management was in the hands of the main partner Gesundheit Österreich GmbH, Geschäftsbereich Österreichisches Bundesinstitut für Gesundheitswesen / Austrian Health Institute (PPRI Secretariat) and the associated partner World Health Organisation, Regional Office for Europe (WHO Europe).

In the course of the project, the PPRI network was established, covering 52 institutions from a total of 31 countries (all EU Member States except Romania, plus Albania, Canada, Norway, Switzerland, and Turkey). The majority of the participating institutions are national authorities, mainly Ministries of Health, Medicines Agencies and third party payers. Additionally, international institutions (European Medicines Agency, OECD, WHO and World Bank) and representatives of related initiatives (e.g., Medicine Evaluation Committee) and projects (e.g., EUROMEDSTAT project, SOGETI Pharmaceutical Indicators project, Andalusian School of Public Health/EASP) joined the network. The PPRI network meets on a regular basis, an overview is given under PPRI Meetings


The PPRI project produced several deliverables, among those:

  • the establishment of the sustainable PPRI Members and organisation of several PPRI Meetings
  • the PPRI Website (, providing several publications produced by PPRI and an intranet forum for PPRI participants,
  • the results of a Needs Assessment, exploring the expectations of more than 110 national and European institutions with regard to the information needs on pharmaceutical pricing and reimbursement. For the Needs Assessment Report see PPRI Report
  • the PPRI Glossary, which is a unique glossary of pharmaceutical terms to establish a common "pharma" terminology within the EU. See Glossary
  • more than 20 country reports on pharmaceutical pricing and reimbursement, the so-called PPRI Pharma Profiles, written by national experts, mostly from the institutions being responsible for pricing and reimbursement. See Country information
  • a set of core indicators to compare information of different pharmaceutical system. See the Indicators
  • a comparative analysis, based on the developed indicators, filled with real data from 27 PPRI countries. The PPRI comparative analysis is included in the PPRI Report and summed up in the concise report Concise information
  • the PPRI Conference, held in Vienna in June 2007